GLAND vs JAGSNPHARM: Stock Comparison
GLAND PHARMA is the larger company by market capitalisation. GLAND PHARMA shows faster revenue growth, a higher ROCE and a higher net margin, while JAGSONPAL PHARMACEUTICALS shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
GLAND leads 9; JAGSNPHARM leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | GLAND | JAGSNPHARM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | GLAND | JAGSNPHARM |
|---|---|---|
| Live Price | ₹2,922.3 | ₹232.89 |
| Day Change | -0.83% | -0.04% |
| Volume | 3.89 L | 51,421 |
| 52-Week High | ₹3,042 | ₹264.5 |
| 52-Week Low | ₹1,573.6 | ₹155 |
| Distance from 52W High | -3.93% | -11.95% |
Valuation
| Metric | GLAND | JAGSNPHARM |
|---|---|---|
| Market Cap | ₹48,333 Cr | ₹1,537 Cr |
| P/E Ratio | 42.78x | 34.02x |
| P/B Ratio | 4.66x | 5.64x |
| EPS | ₹22.09 | ₹2 |
| Book Value | ₹627.91 | ₹41.95 |
| Dividend Yield | 0.68% | 2.78% |
Growth
| Metric | GLAND | JAGSNPHARM |
|---|---|---|
| Revenue Growth (TTM YoY) | 22.3% | 9.6% |
| EPS Growth (TTM YoY) | 96.4% | 23.8% |
| Qtr Sales Growth | -28.53% | -71.37% |
| Qtr Profit Growth | 14.96% | -69.39% |
Profitability & Leverage
| Metric | GLAND | JAGSNPHARM |
|---|---|---|
| ROE | 12.02% | 15.6% |
| ROCE | 17.2% | 16.48% |
| Net Margin | 16.18% | 15% |
| Operating Margin | 38.8% | 20.38% |
| Debt to Equity | 0x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | GLAND | JAGSNPHARM |
|---|---|---|
| Promoter Holding | 51.77% | 25.55%▲ 0.43 pp |
| FII Holding | 8.74%▲ 1.44 pp | 2.3%▼ 0.14 pp |
| DII Holding | 30.44%▼ 2.91 pp | 0.62%▲ 0.4 pp |
| Public Holding | 9.05%▲ 1.53 pp | 28.03%▼ 1.42 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GLAND PHARMA and JAGSONPAL PHARMACEUTICALS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.